BRCA2 and ovarian cancer: In high-grade serous ovarian cancer, BRCA1/BRCA2 gene mutations are important players in the HR pathway and account for 20% of patients with ovarian cancer with BRCA1/BRCA2 somatic or germline mutations (23).